Harvard Bioscience (HBIO) Getting Favorable Media Coverage, Report Shows

Media stories about Harvard Bioscience (NASDAQ:HBIO) have trended positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Harvard Bioscience earned a news impact score of 0.31 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 44.2950424767752 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

HBIO has been the subject of several research analyst reports. Benchmark upped their price target on shares of Harvard Bioscience from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. Janney Montgomery Scott upped their price target on shares of Harvard Bioscience from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $6.92.

Harvard Bioscience (NASDAQ HBIO) opened at $4.70 on Friday. Harvard Bioscience has a 1 year low of $2.25 and a 1 year high of $4.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40. The firm has a market cap of $163.94, a PE ratio of -52.22 and a beta of 1.39.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/harvard-bioscience-hbio-getting-favorable-media-coverage-report-shows.html.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply